IGF-1 LR3 (Long R3 IGF-1) is a recombinant, 83-amino-acid analogue of human insulin-like growth factor 1. It is one of the more misunderstood reagents in the research-peptide catalogue: the name carries a lot of gym folklore, while the actual molecule is a well-characterised laboratory tool with a specific documented origin, a specific documented purpose, and a specific documented liability. This guide covers the two structural changes that define it, why those changes matter more than they first appear, how the molecule signals, what it has genuinely been studied for, and where the evidence stops.

Everything below is reference material describing published research in cells and animals. IGF-1 LR3 is supplied strictly as a laboratory research reagent, not for human consumption, not for diagnostic or therapeutic use. There is no approved human indication for it, and nothing here is a protocol.

The starting point: native IGF-1 and the IGFBP problem

Native human IGF-1 is a single-chain polypeptide of 70 amino acids, structurally related to proinsulin, and the principal mediator of growth hormone's anabolic signalling. It acts mainly through the type 1 IGF receptor (IGF-1R), a receptor tyrosine kinase.

The critical detail, the one that explains why IGF-1 LR3 exists at all, is that circulating IGF-1 is almost never free. The great majority of it is captured by a family of six high-affinity IGF-binding proteins (IGFBP-1 through IGFBP-6), predominantly IGFBP-3, which carries IGF-1 in a ternary complex with the acid-labile subunit [3]. These binding proteins are not passive carriers. They serve as a circulating reservoir, they extend the peptide's residence time in plasma, and, most importantly for anyone working with IGF-1 in an experiment, they sequester the ligand and restrict its access to the receptor [3][4].

For a researcher, this creates a practical problem. Add native IGF-1 to a serum-containing culture, or infuse it into an animal, and a large and variable fraction of what you added is immediately mopped up by IGFBPs that were already there. The effective, receptor-available concentration is therefore both much lower than the nominal one and difficult to control. The IGF system's own regulatory machinery works directly against experimental reproducibility.

What IGF-1 LR3 actually is: two changes to one molecule

IGF-1 LR3 is native IGF-1 with two independent modifications, each of which was worked out separately before being combined. Both exist for the same reason: to get the peptide away from the binding proteins.

1. The Glu3 to Arg substitution, the "R3"

In 1988, Bayne and colleagues at Merck produced a systematic series of human IGF-1 structural analogues to map which regions of the molecule are responsible for binding serum binding proteins versus the receptors. They found the N-terminal region to be decisive: analogues altered there showed markedly reduced affinity for the serum binding proteins and for the type 2 IGF receptor, while retaining IGF-1R binding [1]. The arginine-for-glutamate swap at position 3, hence "R3", was introduced later, by Francis and colleagues in 1992, and is the change that survived into the reagent used today [2].

2. The 13-residue N-terminal extension, the "Long"

The second modification adds a 13-amino-acid extension peptide (MFPAMPLSSLFVN) to the N-terminus. Its origin is partly practical: the extension derives from the recombinant fusion-protein expression system used to produce the analogue in bacteria, and it improves expression and recovery. But it is not merely a manufacturing artefact left in place for convenience, it further weakens IGFBP association, compounding the effect of the Arg3 substitution [2].

70 native residues plus 13 extension residues gives the 83-amino-acid chain that defines the molecule. Note that the "R3" name refers to position 3 of the native IGF-1 sequence, not position 3 of the 83-residue construct, a small point that causes recurring confusion when people try to read the substitution off the full sequence.

What the combination bought

Francis and colleagues characterised these recombinant fusion protein analogues in 1992 and compared them head to head. Their conclusion is worth stating precisely, because it is the entire rationale for the molecule: the enhanced biological potency of these analogues was driven principally by their reduced IGF-binding-protein affinity rather than by any improvement in receptor binding [2]. LR3 IGF-1 does not bind IGF-1R better than native IGF-1 does, in fact its receptor affinity is somewhat lower. It is more potent in biological systems because far more of it stays free and available to reach that receptor.

Why escaping the IGFBPs changes the pharmacology

The consequence is a large shift in free fraction. In any system where IGFBPs are present, serum-supplemented culture medium, or a living animal, LR3 IGF-1 behaves as though a much higher concentration of native IGF-1 had been added, because the buffering step that normally absorbs most of the dose barely engages.

The clearest quantification comes from Tomas and colleagues, who administered IGF-1 and LR3 IGF-1 to growing female rats over 14 days via subcutaneously implanted osmotic pumps. Both peptides increased body weight gain, nitrogen retention and food conversion efficiency in a dose-dependent way. LR3 IGF-1 was substantially the more potent of the two: roughly 44 µg/day of the variant produced effects comparable to 278 µg/day of native IGF-1, an approximately six-fold difference in potency [8]. The authors' summary of the mechanism matches the design intent exactly: IGF-1 variants that bind less well to IGF-binding proteins are more active than IGF-1 itself. Those figures describe what was infused into rats in that study; they are not, and cannot be converted into, a dose for anything else.

The half-life claim that does not survive checking

A widely repeated claim holds that IGF-1 LR3 has a dramatically extended half-life, figures in the range of 20 to 30 hours circulate freely, supposedly because it evades the binding proteins. This gets the pharmacology backwards, and it is worth being direct about it.

IGFBP binding is what prolongs IGF-1's residence in plasma; the bound pool is a reservoir that protects the peptide from clearance. Remove the binding and you remove the reservoir. The relevant measurement comes from Ballard and colleagues, who compared plasma clearance of labelled IGF-1, IGF-2 and des(1-3)IGF-1 in rats. des(1-3)IGF-1, which shares LR3's defining property of very weak IGFBP binding, was cleared markedly faster than intact IGF-1, with mean total plasma clearances of 4.59 versus 1.20 ml/min per kg, close to a four-fold difference; most of the des(1-3)IGF-1 radioactivity remained free rather than binding-protein-associated [5].

That is measured on des(1-3)IGF-1 rather than on LR3 IGF-1, so it is an inference by analogy rather than a direct measurement, and we flag it as such. But the direction is mechanistically clear, and the commonly cited long half-life figures for LR3 do not trace back to a clean primary source. Higher potency in the LR3 literature comes from a larger free fraction, not from persistence.

IGF-1 LR3 vs native IGF-1 vs des(1-3)IGF-1

These three are constantly conflated. They are distinct molecules with distinct behaviour:

  • Native IGF-1, 70 residues, unmodified. Binds IGFBPs with high affinity, so most of it is sequestered; long plasma residence in the bound pool, small free fraction, and its effective activity depends heavily on the IGFBP profile of whatever system it is in.
  • des(1-3)IGF-1, a truncated analogue, 67 residues, produced by removing the N-terminal tripeptide Gly-Pro-Glu. It reaches weak IGFBP binding by subtraction. Retains IGF-1R affinity, is more potent than native IGF-1 in IGFBP-containing systems, and clears from plasma faster [5].
  • IGF-1 LR3, an extended and substituted analogue, 83 residues. It reaches weak IGFBP binding by two combined changes rather than by truncation, and the N-terminal extension additionally suits recombinant production [2].

The shared theme is that des(1-3)IGF-1 and LR3 IGF-1 are two different engineering routes to the same objective, an IGF-1 that the binding proteins largely ignore, and both were developed by overlapping groups in the same era for the same experimental reason.

Signalling: IGF-1R, PI3K/Akt and MAPK

Once free, IGF-1 LR3 does what IGF-1 does: it engages IGF-1R. Ligand binding activates the receptor's intrinsic tyrosine kinase, which autophosphorylates and recruits the IRS family of adaptor proteins and Shc. From there the signal splits into two principal arms [6]:

  • IRS → PI3K → Akt, the metabolic and pro-survival arm, running downstream to mTOR, GSK3 and the FoxO transcription factors. This branch governs protein synthesis, glucose uptake and suppression of apoptosis.
  • Shc → Ras → Raf → MEK → ERK (MAPK), the mitogenic arm, associated with proliferation and gene-expression changes driving cell-cycle entry.

Which arm dominates is cell-type and context dependent, and the distinction is not academic. In cultured skeletal myotubes, Rommel and colleagues showed that IGF-1-induced hypertrophy is mediated specifically through PI3K/Akt/mTOR and PI3K/Akt/GSK3 signalling [7], the hypertrophic readout tracks the Akt branch. IGF-1R signalling also cross-talks with insulin receptor signalling, which the two receptors' close homology makes unavoidable, and at sufficient concentration IGF-1 analogues can engage insulin receptors, relevant background to the metabolic effects reported in the IGF literature.

What IGF-1 LR3 is actually used for

Cell culture, its most established application

The best-documented real-world use of Long R3 IGF-1 is unglamorous and has nothing to do with animals: it is a cell-culture supplement, used as a more potent and more stable substitute for insulin in serum-free industrial cell culture. Morris and Schmid examined exactly this, showing the effects of insulin and LongR3 on serum-free Chinese hamster ovary (CHO) cell cultures expressing two recombinant proteins [9]. Because serum-free media lack the IGFBPs that would otherwise sequester the growth factor, and because LR3 is active at much lower concentrations than insulin, it supports proliferation and productivity in bioreactor culture. This is the application the molecule was effectively productised for, and it is a genuinely useful research reagent in that role.

Proliferation, hypertrophy and metabolism models

Beyond culture, LR3 IGF-1 appears in the preclinical literature as a tool for interrogating the IGF axis where IGFBP interference would confound the readout, anabolic and nitrogen-balance studies in rodents [8], and models probing IGF-1R-dependent proliferation and growth. The value of the analogue in these settings is methodological: it isolates receptor-level effects from binding-protein effects, which native IGF-1 cannot do.

The proliferation and oncology concern

This is the section that decides how the molecule should be classified, and it is not a disclaimer bolted on at the end, it follows directly from the mechanism described above.

IGF-1R signalling is mitogenic and anti-apoptotic. Those are not side effects; they are the pathway working as designed. The same PI3K/Akt and Ras/MAPK arms that drive protein synthesis and cell survival are among the most thoroughly documented pro-tumorigenic signalling routes in cancer biology. Pollak's review of insulin and IGF signalling in neoplasia lays out the case in detail: IGF-1R activation supports proliferation, protects transformed cells from apoptosis, and contributes to tumour progression, which is precisely why IGF-1R has been pursued as an oncology drug target, the therapeutic interest is in blocking this receptor, not stimulating it [10].

The epidemiology points the same way. Renehan and colleagues' systematic review and meta-regression analysis found that higher circulating IGF-1 concentrations were associated with increased risk of certain cancers, prostate and premenopausal breast cancer among them [11]. That is an association in observational data at physiological ranges, and it does not establish causation, but the honest reading is that it is consistent with, not reassuring against, the mechanistic concern.

Now combine the two facts. IGF-1 LR3 is engineered specifically to defeat the body's principal mechanism for controlling how much free IGF-1 reaches the receptor, and it is roughly six-fold more potent than native IGF-1 in vivo [8]. The IGFBP system it circumvents is a regulatory brake. A compound whose entire design premise is sustained, unbuffered stimulation of a well-established proliferative and anti-apoptotic receptor is a compound with an unquantified proliferation liability, including the possibility of promoting growth of pre-existing, undetected neoplastic cells. No study has characterised that risk in humans, because the appropriate study has not been done and would not be approved.

This is the concrete reason IGF-1 LR3 is a research reagent and nothing else. It is not a regulatory technicality or a legal formality. It is the correct classification given what the molecule does.

Limits of the evidence

An honest account of what is not known here is longer than most sources admit:

  • The evidence base is rodent- and cell-culture-dominated. The formative in vivo work on LR3 IGF-1 is rat studies from the early 1990s [8], with small group sizes by modern standards. Rodent IGF and IGFBP physiology is not identical to human physiology.
  • There are no controlled human trials of IGF-1 LR3. Not few, none of consequence. Every claim about how it behaves in a human body is extrapolation across species from a handful of animal experiments.
  • No approved indication exists anywhere. Recombinant native IGF-1 (mecasermin) has a narrow approved use in severe primary IGF-1 deficiency; that approval says nothing about LR3, which is a different molecule with deliberately different binding behaviour.
  • Its pharmacokinetics are poorly characterised. As set out above, the widely repeated half-life figures lack a clean primary source, and the nearest direct measurement is on a related but distinct analogue [5].
  • Long-term safety data do not exist in any species at any exposure relevant to the folklore, and the proliferation concern above is precisely the kind of risk that only long-term data could address.
  • Reagent identity and purity are live variables. An 83-residue recombinant peptide can be misidentified, truncated, or simply be something else; without analytical characterisation of the specific batch, the published literature does not necessarily describe what is in the vial.

Handling and characterisation

IGF-1 LR3 is supplied as a lyophilised powder, which is how peptides of this size are stabilised for storage and shipping. As a recombinant protein it is more conformationally fragile than a short synthetic peptide: it is sensitive to heat, to repeated freeze-thaw cycling, and to vigorous agitation, any of which can denature or aggregate it and silently cost activity without any visible change. In vitro work reconstitutes material like this in sterile water, PBS, or dilute acetic acid, chosen to suit the assay; bacteriostatic water is a diluent for multi-dose human injectables, not a laboratory default. General principles for reconstituting lyophilised material are covered in our monograph on bacteriostatic water.

Because identity and purity are, as noted, live variables for this class, batch-level analytics matter more than the label. Our IGF-1 LR3 product page lists the specification and the batch certificate of analysis for the material we stock, so the identity and purity of the specific lot can be checked rather than assumed.

Research use only

This article is compiled from publicly available peer-reviewed literature and is provided for reference and informational purposes only. It is not medical advice and not a recommendation for use. IGF-1 LR3 is an experimental compound and is not an approved medicine in any jurisdiction. Products referenced here are supplied strictly for laboratory research purposes, they are not intended for human consumption, nor for diagnostic or therapeutic application. All quantities and results described above were obtained under controlled experimental conditions in cells or animals and must not be read as instructions.

The full list of sources with links, is in the monograph: IGF-1 LR3.